Fighting Ebola: A Window for Vaccine Re-evaluation?

PLoS Pathogens

Volumn 13, Issue 1, 2017, Pages

  Chappell, Keith J ^a   Watterson, Daniel ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; MUCIN;

ARTHRITIS; ARTHROCENTESIS; ARTICLE; BURIAL; COMMUNICABLE DISEASE; CONTACT EXAMINATION; CYTOPATHOGENIC EFFECT; DRUG SAFETY; EBOLAVIRUS; FILOVIRUS; HUMAN; IMMUNOGENICITY; MORTALITY RATE; PATIENT ISOLATION; PHASE 1 CLINICAL TRIAL (TOPIC); TROPISM; VESICULOVIRUS; VIREMIA; EBOLA HEMORRHAGIC FEVER; IMMUNOLOGY;

EBOLA VACCINES; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 85011003461     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006037     Document Type: Article

References (38)

1. Martins KA, Jahrling PB, Bavari S, Kuhn JH, (2016) Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines15: 1101–1112. doi: 10.1080/14760584.2016.118756627160784
2. Keshwara R, Johnson RF, Schnell MJ, (2016) Toward an Effective Ebola Virus Vaccine. Annu Rev Med.
3. Wang Y, Li J, Hu Y, Liang Q, Wei M, et al. (2016) Ebola vaccines in clinical trial: the promising candidates. Hum Vaccin Immunother: 0.
4. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, et al. (2011) Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol85: 4222–4233. doi: 10.1128/JVI.02407-1021325402
5. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, et al. (2014) Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med20: 1126–1129. doi: 10.1038/nm.370225194571
6. De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, et al. (2016) Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis16: 311–320. doi: 10.1016/S1473-3099(15)00486-726725450
7. Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, et al. (2016) Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA315: 1610–1623. doi: 10.1001/jama.2016.421827092831
8. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, et al. (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet386: 857–866. doi: 10.1016/S0140-6736(15)61117-526248676
9. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, et al. (2016) Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med374: 1647–1660. doi: 10.1056/NEJMoa150292425830326
10. Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, et al. (2015) First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). Open Forum Infect Dis2: ofv082. doi: 10.1093/ofid/ofv08226199949
11. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, et al. (2000) Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med6: 886–889. doi: 10.1038/7864510932225
12. Okumura A, Pitha PM, Yoshimura A, Harty RN, (2010) Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol84: 27–33. doi: 10.1128/JVI.01462-0919846529
13. Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, et al. (2015) Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med7: 304ra142. doi: 10.1126/scitranslmed.aaa386326355031
14. Denner J, (2015) Treatment of Ebola virus infections with inhibitors of TLR4. Med Hypotheses85: 253–257. doi: 10.1016/j.mehy.2015.05.00926003830
15. Hacke M, Bjorkholm P, Hellwig A, Himmels P, de Almodovar CR, et al. (2015) Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol. Nat Commun6: 7688. doi: 10.1038/ncomms868826158910
16. Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, et al. (2004) Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J23: 2175–2184. doi: 10.1038/sj.emboj.760021915103332
17. Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE, (2014) Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog10: e1004509. doi: 10.1371/journal.ppat.100450925412102
18. Dolnik O, Volchkova VA, Escudero-Perez B, Lawrence P, Klenk HD, et al. (2015) Shedding of Ebola Virus Surface Glycoprotein Is a Mechanism of Self-regulation of Cellular Cytotoxicity and Has a Direct Effect on Virus Infectivity. J Infect Dis212Suppl 2: S322–328.
19. Martinez O, Tantral L, Mulherkar N, Chandran K, Basler CF, (2011) Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis204Suppl 3: S825–832.
20. Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K, (2010) A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J Virol84: 163–175. doi: 10.1128/JVI.01832-0919846533
21. Morales M, Nnadi CD, Tangermann RH, Wassilak SG, (2016) Notes from the Field: Circulating Vaccine-Derived Poliovirus Outbreaks—Five Countries, 2014–2015. MMWR Morb Mortal Wkly Rep65: 128–129. doi: 10.15585/mmwr.mm6505a526866942
22. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, et al. (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol78: 5458–5465. doi: 10.1128/JVI.78.10.5458-5465.200415113924
23. GlaxoSmithKlineStudy to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 Oct 28]. https://clinicaltrials.gov/ct2/show/NCT02548078.
24. Vaccines Janssen, Prevention B.V., EBOVAC2_ConsortiumSafety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 Oct 28]. https://clinicaltrials.gov/ct2/show/NCT02564523.
25. Lai L, Davey R, Beck A, Xu Y, Suffredini AF, et al. (2015) Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA313: 1249–1255. doi: 10.1001/jama.2015.199525742465
26. Marzi A, Hanley PW, Haddock E, Martellaro C, Kobinger G, et al. (2016) Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. J Infect Dis214: S360–S366. doi: 10.1093/infdis/jiw21827496978
27. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, et al. (2008) Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol82: 5664–5668. doi: 10.1128/JVI.00456-0818385248
28. Wang H, Shi Y, Song J, Qi J, Lu G, et al. (2016) Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Cell164: 258–268. doi: 10.1016/j.cell.2015.12.04426771495
29. Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, et al. (2016) Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol1: 16128. doi: 10.1038/nmicrobiol.2016.12827562261
30. Gong X, Qian H, Zhou X, Wu J, Wan T, et al. (2016) Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection. Cell165: 1467–1478. doi: 10.1016/j.cell.2016.05.02227238017
31. Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, et al. (2016) Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. MBio7: e02154–02115. doi: 10.1128/mBio.02154-1526908579
32. Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, et al. (2016) Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science351: 1343–1346. doi: 10.1126/science.aad611726917592
33. Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, et al. (2016) Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science351: 1078–1083. doi: 10.1126/science.aad578826912366
34. CDCMurphy FA, (1975) Negatively-stained transmission electron micrograph (TEM) of vesicular stomatitis virus (VSV) virions. Public Health Image Library—Centers for Disease Control and Prevention.
35. CDCMurphy FA, (1976) Transmission electron micrograph of filamentous Ebola virus. Emerging Infectious Diseases—Centers for Disease Control and Prevention.
36. Zhao Y, Ren J, Harlos K, Jones DM, Zeltina A, et al. (2016) Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature535: 169–172. doi: 10.1038/nature1861527362232
37. Tran EE, Simmons JA, Bartesaghi A, Shoemaker CJ, Nelson E, et al. (2014) Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. J Virol88: 10958–10962. doi: 10.1128/JVI.00870-1425008940
38. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, et al. (2014) Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A111: 17182–17187. doi: 10.1073/pnas.141416411125404321